Published in Osteoporos Int on July 19, 2007
Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc (2010) 2.32
Secular trends in hip fracture incidence and recurrence. Osteoporos Int (2008) 2.04
Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int (2009) 0.97
Prevention and clinical management of hip fractures in patients with dementia. Geriatr Orthop Surg Rehabil (2010) 0.94
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int (2009) 0.87
Treatment of osteoporosis in postmenopausal hip fracture patients after geriatric rehabilitation: changes over the last decade. Z Gerontol Geriatr (2011) 0.84
Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations. Ther Adv Chronic Dis (2010) 0.80
Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study. J Bone Miner Metab (2011) 0.76
Effect of bisphosphonate initiation at week 2 versus week 12 on short-term functional recovery after femoral neck fracture: a randomized controlled trial. Arch Osteoporos (2017) 0.75
Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies. Am J Epidemiol (2016) 0.75
Secular trends in incidence and recurrence rates of hip fracture: a nationwide population-based study. Osteoporos Int (2016) 0.75
Established Osteoporosis and Gaps in the Management: Review from a Teaching hospital. Ann Med Health Sci Res (2014) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol (1993) 13.16
Epidemiology and outcomes of osteoporotic fractures. Lancet (2002) 13.09
Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med (1995) 13.01
Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 12.60
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc (2006) 8.78
Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet (1999) 7.14
Effect of Vitamin D on falls: a meta-analysis. JAMA (2004) 6.64
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Osteoporosis. Lancet (2006) 5.40
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
Assessment of fracture risk. Osteoporos Int (2004) 5.15
Risk factors for serious injury during falls by older persons in the community. J Am Geriatr Soc (1995) 4.78
Estimating treatment effects using observational data. JAMA (2007) 4.12
The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol (1995) 3.99
Estimating medication persistency using administrative claims data. Am J Manag Care (2005) 3.95
Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol (2005) 3.76
Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev (2002) 3.46
Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol (1999) 2.20
Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc (2004) 1.84
Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988-1995. CMAJ (2000) 1.72
Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm (2004) 1.70
Identification of high-risk individuals for hip fracture: a 14-year prospective study. J Bone Miner Res (2005) 1.54
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int (2005) 1.52
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc (2004) 1.44
Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol (2005) 1.44
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ (2005) 1.43
Time trends of mortality after first hip fractures. Osteoporos Int (2007) 1.40
Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord (2005) 1.27
Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int (2006) 1.20
The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin (2004) 1.15
Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res (2006) 1.01
Can historical and functional risk factors be used to predict fractures in community-dwelling older adults? development and validation of a clinical tool. Osteoporos Int (2002) 1.01
Characteristics of elderly patients admitted to an urban tertiary care hospital with osteoporotic fractures: correlations with risk factors, fracture type, gender and ethnicity. Osteoporos Int (2005) 0.98
Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord (2002) 0.92
The Harstad injury prevention study: the characteristics and distribution of fractures amongst elders--an eight year study. Int J Circumpolar Health (1999) 0.92
Prevalence of vitamin D inadequacy in osteoporotic hip fracture patients in London. Curr Med Res Opin (2005) 0.91
Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses. J Manag Care Pharm (2006) 0.89
To treat or not to treat, that is the question: proceedings of the Quebec symposium for the treatment of osteoporosis in long-term care institutions, Saint-Hyacinthe, Quebec, November 5, 2004. J Am Med Dir Assoc (2007) 0.85
Guidelines for the management of osteoporosis: the present and the future. Osteoporos Int (2005) 0.83
The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. Semin Arthritis Rheum (2006) 0.82
Patients with hip fracture: what can be improved? Bone (2006) 0.79
Rapid prevention of vertebral fractures associated with osteoporosis. Orthopedics (2005) 0.75
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med (1997) 4.18
HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample. JAMA (1994) 3.80
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol (1996) 3.39
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol (1997) 3.29
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Cyclic adenosine monophosphate, CA++, and membranes. Proc Natl Acad Sci U S A (1968) 2.46
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A (2001) 2.30
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J Cell Biol (1994) 2.00
Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc Natl Acad Sci U S A (2001) 1.88
Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev (2012) 1.88
The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2008) 1.86
Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimulating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy. Proc Natl Acad Sci U S A (1983) 1.75
Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol Cell Biol (1995) 1.73
Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int (2000) 1.72
A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int (2002) 1.70
Evidence for a humoral mechanism for enhanced osteogenesis after head injury. J Bone Joint Surg Am (1990) 1.64
Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. Br J Psychiatry (2013) 1.58
The transcription factor SOX9 regulates cell cycle and differentiation genes in chondrocytic CFK2 cells. J Biol Chem (2001) 1.51
The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2007) 1.48
The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2003) 1.47
Programmed cell death of chondrocytes and aberrant chondrogenesis in mice homozygous for parathyroid hormone-related peptide gene deletion. Endocrinology (1996) 1.46
Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch Intern Med (2000) 1.44
Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition. Endocrinology (2001) 1.43
The role of cyclic AMP and calcium in cell activation. CRC Crit Rev Biochem (1972) 1.38
Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab (2008) 1.37
25-Hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. Osteoporos Int (2010) 1.34
Role of Ca 2+ and cyclic AMP in protein secretion from rat exocrine pancreas. Biochim Biophys Acta (1972) 1.32
First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. Eur J Hum Genet (1998) 1.32
Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev Biol (1996) 1.31
The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int (2006) 1.31
Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res (1994) 1.30
Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem (1992) 1.28
Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int (2010) 1.27
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int (2010) 1.24
Malignancy-associated hypercalcemia: evaluation with a cytochemical bioassay for parathyroid hormone. J Clin Endocrinol Metab (1981) 1.24
Purification of peptides with parathyroid hormone-like bioactivity from human and rat malignancies associated with hypercalcemia. Endocrinology (1986) 1.18
In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus. J Biol Chem (2001) 1.17
Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int J Cancer (1999) 1.16
Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res (2003) 1.16
Predictors of quality of life 6 months and 1 year after acute myocardial infarction. Am Heart J (2001) 1.15
Interactions of PTH and PTHrP with the PTH/PTHrP receptor and with downstream signaling pathways: exceptions that provide the rules. J Bone Miner Res (1999) 1.12
Calcitonin receptors in the central nervous system of the rat. Endocrinology (1981) 1.12
Calcitonin as a tumor marker. Use of the radioimmunoassay for calcitonin in the postoperative evaluation of patients with medullary thyroid carcinoma. N Engl J Med (1974) 1.10
Rat parathyroid hormone-like peptide: comparison with the human homologue and expression in malignant and normal tissue. Mol Endocrinol (1989) 1.09
Cloning of human PEX cDNA. Expression, subcellular localization, and endopeptidase activity. J Biol Chem (1998) 1.08
Attitudes of women toward hormone therapy and prevention of heart disease. Am Heart J (1995) 1.07
Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther (2005) 1.07
Parathyroid-hormone-related peptide in hematologic malignancies. Am J Med (1996) 1.07
The parathyroid hormone-like peptide gene is expressed in the normal and neoplastic human endocrine pancreas. Mol Endocrinol (1989) 1.06
Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway. J Biol Chem (2001) 1.05
Age-related differences in in-hospital mortality and the use of thrombolytic therapy for acute myocardial infarction. CMAJ (2001) 1.04
Therapeutic potential of non-adherent BM-derived mesenchymal stem cells in tissue regeneration. Bone Marrow Transplant (2008) 1.04
Regulation of expression of the chondrocytic phenotype in a skeletal cell line (CFK2) in vitro. J Bone Miner Res (1993) 1.03
Direct in vivo demonstration by radioautography of specific binding sites for calcitonin in skeletal and renal tissues of the rat. J Cell Biol (1980) 1.03
Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology (2002) 1.03
Characterization of the human parathyroid hormone-like peptide gene. Functional and evolutionary aspects. J Biol Chem (1989) 1.03
Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest (1987) 1.03
Variance component linkage analysis indicates a QTL for femoral neck bone mineral density on chromosome 1p36. Hum Mol Genet (2001) 1.03
The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res (2000) 1.03
Interaction of calcitonin and calcitonin gene-related peptide at receptor sites in target tissues. Science (1985) 1.02
Enhanced growth of a human keratinocyte cell line induced by antisense RNA for parathyroid hormone-related peptide. J Biol Chem (1992) 1.01
Analysis of the requirements for parathyroid hormone action in renal membranes with the use of inhibiting analogues. J Biol Chem (1975) 1.01
Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum (2000) 1.01
Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology (1989) 1.00
Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. Am J Physiol Endocrinol Metab (2001) 1.00
PTH and PTHrP effects on the skeleton. Rev Endocr Metab Disord (2000) 0.99
Dysregulation of parathyroid hormone-like peptide expression and secretion in a keratinocyte model of tumor progression. Cancer Res (1991) 0.99
Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism. J Bone Miner Res (1990) 0.99
The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2006) 0.98
Proparathyroid hormone-related protein is associated with the chaperone protein BiP and undergoes proteasome-mediated degradation. J Biol Chem (1998) 0.98
Regulation of parathyroid hormone-like peptide in cultured normal human keratinocytes. Effect of growth factors and 1,25 dihydroxyvitamin D3 on gene expression and secretion. J Clin Invest (1991) 0.98
Chemical and biological properties of synthetic, sulfur-free analogues of parathyroid hormone. J Biol Chem (1976) 0.98
New insights into mineral and skeletal regulation by active forms of vitamin D. Kidney Int (2006) 0.97
Effect of EGTA on protein release and cyclic AMP accumulation in rat parotid gland. Can J Physiol Pharmacol (1973) 0.96
Cytochemical bioassay of parathyroid hormone: characteristics of the assay and analysis of circulating hormonal forms. J Clin Invest (1980) 0.96
Tissue-specific targeting of the pthrp gene: the generation of mice with floxed alleles. Endocrinology (2001) 0.95
Thyrocalcitonin, osteoporosis and osteolysis. Am J Med (1967) 0.95
Cell cycle regulation of menin expression. Cancer Res (1999) 0.95
The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study. Aliment Pharmacol Ther (2007) 0.95
Total parathyroidectomy: parathyroid hormone levels and supernumerary glands in hemodialysis patients. Clin Invest Med (1984) 0.95
A mammalian serine/threonine kinase receptor specifically binds BMP-2 and BMP-4. Biochem Biophys Res Commun (1994) 0.94
In vivo distribution of parathyroid hormone receptors in bone: evidence that a predominant osseous target cell is not the mature osteoblast. Endocrinology (1988) 0.94
Seroprevalence of parvovirus B19 infection in daycare educators. Epidemiol Infect (2005) 0.94
The effect of smoking cessation counselling in pregnant women: a meta-analysis of randomised controlled trials. BJOG (2011) 0.94
PTHrP inhibits adipocyte differentiation by down-regulating PPAR gamma activity via a MAPK-dependent pathway. Endocrinology (2001) 0.93
Cell-specific expression of the parathyroid hormone (PTH)/PTH-related peptide receptor gene in kidney from kidney-specific and ubiquitous promoters. Endocrinology (1997) 0.93
Antisense-mediated inhibition of parathyroid hormone-related peptide production in a keratinocyte cell line impedes differentiation. Mol Endocrinol (1994) 0.93
Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2010) 0.93